Omicia and LabCorp Collaborate on Integrated Platform for Genomic Analysis in Clinical Trials

Jun 04, 2014
By Applied Clinical Trials Editors

Omicia, Inc. announced that its clinical next-generation sequencing (NGS) interpretation software will be used by LabCorp® for its clinical trials sequencing services, to offer clients a comprehensive suite of expert tools and services for incorporating genomic data into clinical trials.

The Omicia/LabCorp collaboration addresses the growing demand for NGS-derived biomarker data. This effort also highlights LabCorp’s continued focus on biomarker development to support clinical trial activities. The collaboration will enable customers of both companies to integrate NGS data into clinical trials in a more streamlined way.

Read the full release here.

lorem ipsum